Dr. Daniel Alkon Appointed President of Neurotrope, Inc.

NEW YORK, Sept. 28, 2016

After approximately 30 years directing programs on the molecular basis of associative memory at the National Neurologic Institute of NIH, and another approximately 15 years as the Founding Scientific Director of the Blanchette Rockefeller Neurosciences Institute, Dr. Alkon has now decided to devote much more of his time to the development of drugs to treat neurodegeneration at Neurotrope. Dr. Alkon stated, "It has been a great honor and opportunity to have been a part of the Blanchette Rockefeller Neurosciences Institute and to oversee its discoveries of synaptic regeneration to treat the progression of diseases such as Alzheimer's disease, Fragile X, and Traumatic Brain Injury.  Now, I believe it is crucial that I assume a more important and direct role at Neurotrope.  I believe that Neurotrope's lead drug candidate, now in Phase 2 trials across the nation, has the potential to treat and even possibly reverse the ravages of neurodegeneration and I want to be totally involved in the process to make that happen.   I believe this is a very exciting time to be involved with the company."

Further details may be found in the Company's Form 8-K filing with the Securities and Exchange Commission (SEC).

About Neurotrope         

Neurotrope BioScience, Inc., a wholly owned subsidiary of Neurotrope, Inc., is a biotechnology company focused on developing a novel therapy for the treatment of Alzheimer's disease.   The scientific basis of our treatment is activation of Protein Kinase C isozymes ε and α by bryostatin, a natural product, which in mouse AD models was demonstrated to result in repair and replacement of damaged synapses (synaptogenesis).  PKC epsilon has also exhibited the ability to prevent neuronal death, reduce toxic beta-amyloid and neurofibrillary tangles, and enhance memory and learning, thus having the potential to improve cognition, daily functions, mood and behavior in Alzheimer's disease patients. 

Neurotrope is also conducting preclinical studies of bryostatin as a treatment for Fragile X Syndrome and Niemann-Pick Type C disease, two rare genetic diseases for which only symptomatic treatments are currently available. The FDA has granted Orphan Drug Designation to Neurotrope for bryostatin as a treatment for Fragile X Syndrome.  Bryostatin has undergone testing in over 1,400 people establishing a large safety database.

Neurotrope has exclusively licensed technology from the Blanchette Rockefeller Neurosciences Institute for Alzheimer's disease and Fragile X Syndrome, has a world-wide, exclusive license with the Icahn School of Medicine at Mt. Sinai for Niemann-Pick Type C.   The company has also entered into a collaboration with RettSydrome.org and is partnered with Stanford University to synthesize and find the next generation bryostatin,  called bryologs.